Tissue Regenix Valuation
| TRX Stock | 58.50 0.00 0.00% |
At this time, the company appears to be overvalued. Tissue Regenix Group has a current Real Value of USD48.72 per share. The regular price of the company is USD58.5. Our model measures the value of Tissue Regenix Group from inspecting the company fundamentals such as Shares Outstanding of 71.23 M, operating margin of 0.03 %, and Return On Equity of -0.0331 as well as reviewing its technical indicators and probability of bankruptcy.
Price Book 1.6973 | Enterprise Value 47.4 M | Enterprise Value Ebitda 47.0757 | Price Sales 1.3106 | Forward PE 102.0408 |
Overvalued
Today
Please note that Tissue Regenix's price fluctuation is very steady at this time. Calculation of the real value of Tissue Regenix Group is based on 3 months time horizon. Increasing Tissue Regenix's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Tissue stock is determined by what a typical buyer is willing to pay for full or partial control of Tissue Regenix Group. Since Tissue Regenix is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Tissue Stock. However, Tissue Regenix's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 58.5 | Real 48.72 | Hype 58.5 | Naive 58.27 |
The real value of Tissue Stock, also known as its intrinsic value, is the underlying worth of Tissue Regenix Group Company, which is reflected in its stock price. It is based on Tissue Regenix's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Tissue Regenix's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Tissue Regenix Group helps investors to forecast how Tissue stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Tissue Regenix more accurately as focusing exclusively on Tissue Regenix's fundamentals will not take into account other important factors: Tissue Regenix Cash |
|
Tissue Regenix Total Value Analysis
Tissue Regenix Group is at this time forecasted to have takeover price of 47.4 M with market capitalization of 41.67 M, debt of 9.39 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Tissue Regenix fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
47.4 M | 41.67 M | 9.39 M |
Tissue Regenix Investor Information
About 55.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.7. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tissue Regenix Group recorded a loss per share of 0.01. The entity had not issued any dividends in recent years. The firm had 1:100 split on the 28th of April 2023. Based on the key measurements obtained from Tissue Regenix's financial statements, Tissue Regenix Group is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February.Tissue Regenix Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The latest return on assets of Tissue indicates not a very effective usage of assets in January.Tissue Regenix Ownership Allocation
Tissue Regenix Group shows a total of 71.23 Million outstanding shares. Tissue Regenix Group maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Tissue Regenix Profitability Analysis
The company reported the revenue of 29.49 M. Net Loss for the year was (1.67 M) with profit before overhead, payroll, taxes, and interest of 15.73 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Tissue Regenix's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Tissue Regenix and how it compares across the competition.
About Tissue Regenix Valuation
The stock valuation mechanism determines Tissue Regenix's current worth on a weekly basis. Our valuation model uses a comparative analysis of Tissue Regenix. We calculate exposure to Tissue Regenix's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Tissue Regenix's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 16.1 M | 17 M |
Complementary Tools for Tissue Stock analysis
When running Tissue Regenix's price analysis, check to measure Tissue Regenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tissue Regenix is operating at the current time. Most of Tissue Regenix's value examination focuses on studying past and present price action to predict the probability of Tissue Regenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tissue Regenix's price. Additionally, you may evaluate how the addition of Tissue Regenix to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Stocks Directory Find actively traded stocks across global markets |